A Study to Evaluate the Long-Term Safety of M207 in the Acute Treatment of Migraine
Status:
Completed
Trial end date:
2019-05-17
Target enrollment:
Participant gender:
Summary
This is an open-label, twelve-month safety study. There is a screening period followed by a
run-in period to record migraine activity. Qualified subjects will receive study medication
for up to twelve months for the treatment of multiple migraine attacks. Using the electronic
diary (eDiary) to confirm they are experiencing a qualified migraine, subjects will
self-administer the patches and respond to questions in the eDiary post treatment
administration.